Menin-MLL inhibitors and methods of use thereof
US9212180B2 · kind B2 · utility
2Cited by
4References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 11, 2014 |
| Grant date | Dec 15, 2015 |
| Priority date | — |
| Expiry date | Jun 11, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates generally to compounds that inhibit the binding of menin and MLL or MLL fusion proteins and methods of use thereof. In particular embodiments, the present invention provides compositions comprising piperidine-containing compounds and methods of use thereof to inhibit the interaction of menin with MLL oncoproteins (e.g., MLL1, MLL2, MLL-fusion oncoproteins), for example, for the treatment of leukemia, solid cancers, diabetes, and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, MLL-PTD and/or menin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.